Willard Ransom
Family Medicine · Ottawa, KSNPI 1225064801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 271 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 16.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,544 and has fallen 97.0% since, to $46 in 2023.
Across 271 payments — averaging $15.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$670
- AbbVie$631
- Novo Nordisk$555
- Boehringer Ingelheim$218
- Lilly USA, LLC$214
- Amgen$197
- plus $2K from 26 others
What the payments were for
- Consulting fees$251%
- Food & beverage$4,16899%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 22 | $670 |
| AbbVie(2 entities) | 35 | $631 |
| Novo Nordisk | 41 | $555 |
| Boehringer Ingelheim | 14 | $218 |
| Lilly USA, LLC | 16 | $214 |
| Amgen | 12 | $197 |
| Johnson & Johnson | 13 | $175 |
| Pfizer | 16 | $169 |
| Sunovion Pharmaceuticals Inc. | 14 | $159 |
| Sanofi-aventis U.S. LLC | 10 | $143 |
| GSK | 9 | $125 |
| Daiichi Sankyo Inc. | 8 | $109 |
| Amarin Pharma, Inc. | 6 | $83 |
| Merck | 6 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $65 |
| Astellas Pharma US Inc | 5 | $59 |
| Biohaven Pharmaceuticals, Inc. | 4 | $58 |
| Mylan Specialty L.p. | 4 | $56 |
| Biogen | 3 | $54 |
| Abbott | 2 | $50 |
| Kowa Pharmaceuticals America, Inc. | 4 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $40 |
| Sanofi Pasteur Inc. | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Bayer | 2 | $25 |
| Antares Pharma, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,193 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Ottawa
- John GollierOttawa$11K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
- Kyle PlatzManhattan$51K
- Eric AspinwallKansas City$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.